GEPS in search for new CIO New CIO of Korea’s public pension fund expected to be named by May 13
Translated by Ryu Ho-joung 공개 2022-04-06 08:09:55
이 기사는 2022년 04월 06일 08:05 thebell 에 표출된 기사입니다.
South Korea’s Government Employees Pension Service (GEPS) is looking for a new chief investment officer as the tenure of the current CIO, Seo Won-joo, ends in May.The application deadline is April 15. Candidate screening and interviews will follow, with a new CIO expected to be appointed by May 13.
Seo stepped into the role in 2019 for a two-year term and his term was extended by one year. Some expected his term to be extended again, but GEPS opted to find a new investment chief this time.
With Seo leaving his position, this could change the pension fund’s investment strategy. Under Seo’s term, GEPS has expanded investment in alternative assets, such as private equity and private debt, and overseas markets to enhance returns.
The pension fund gained 9.56% in 2019, the first year of Seo’s term, up from negative 2.7% in 2018. It logged 11.41% and 9.7% returns in 2020 and 2021 respectively. Its alternative investments returned 19.37%, the highest among asset classes, followed by equities which gained 15.74%, while fixed income allocation lost 1.17%.
GEPS has reportedly been assessing an option to commit up to $150 million to three foreign private equity or private debt funds. But as Seo is set to be replaced, there could be changes to the fund’s investment plans.
With the process to hire a new CIO underway, the timeline for the fund’s selection of asset managers for alternative investments is also expected to be confirmed later than previous years. (Reporting by Gyoung-tae Kim)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '사랑의열매' OCIO, NH증권 수성 여부 촉각
- 다올운용 라인업 확대 '총력'…해외재간접 펀드 출시
- [스튜어드십코드 모니터]브이아이운용, 현대엘리 표대결서 이사회측 손들었다
- [스튜어드십코드 모니터]다올운용, 삼성전자 이사 후보 '리스크 관리 미흡'
- [성과연동 펀드판매 확산]당국 눈치보며 쉬쉬…법령해석 재확인후 '본격화' 조짐
- [동구바이오제약 신사업 전략]캐시카우만으론 역부족, 벌크업 기반 '오너 보증 차입'
- [LK삼양 뉴비기닝]그룹 오너 구본욱의 변신, 경쟁력 강화만 본다
- [루키 바이오텍 in market]김권 셀비온 대표"경쟁약 넘는 효능, 품목허가 꿈 도전"
- [Policy Radar]바이오시밀러 문턱 낮춘 유럽, 비용·경쟁 판이 바뀐다
- [보험사 IFRS17 조기도입 명암]MG손보, 자본잠식 벗어났지만 결손금 두 배 늘었다